Effect of Blood Pressure Lowering Therapy in Stroke Patients
Objective: The objective of the study is to assess the effect of blood pressure lowering with Candesartan in patients with stroke and elevated blood pressure admitted in this hospital.
Study Design: Prospective descriptive observational study.
Setting: Neurosurgery, Medical Emergency / OPD, Lady Reading Hospital, Peshawar.
Materials and Methods: This descriptive study was done at the Department of Medicine and Neurosurgery, Postgraduate Medical Institute, Lady Reading Hospital Peshawar from January 2013 to May 2014 (for One year and 5 months period) in a total of 357 patients. In this descriptive study, patients presenting to Emergency department or OPD with stroke and elevated blood pressure, presenting within 30 hours of symptom onset and with SBP ≥ 140 mmHg, diastolic > 90 mmHg, were eligible for inclusion. Exclusion criteria were contraindicat-ions to or ongoing treatment with an angiotensin receptor blocker, markedly reduced consciousness, patients with chronic heart failure and intolerance to ACE inhibitors, patient unavailability for follow-up and pregnancy or breast – feeding. The acute phase treatment was a fixed dose of 4 mg on day 1, 8 mg on day 2 and 16 mg on days 3 to 7. Blood pressure was measured daily with the patient in the supine position using a blood pressure monitor. All patients were follow-up on day 7 and at 1 and 6 months after discharged from hospital.
Results: Among 357 cases, 68.06% were males and 31.93% females. Majority (37.25%) belongs to age group of 61 – 70 years. Out of these, 66.10% patients were found to have ischemic and 33.89% patients had hemorrhagic stroke. Highest (40.05%) patients belonged to severe hypertensive group i.e. ≥ 180/110 mmHg. Target was achieved in 75.91% patients.
Conclusions: Our data suggests that lowering BP in acute ICH is probably safe; however, it remains to be seen if this decreases hematoma expansion or improves outcome.
2. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Dise-ase Study. Lancet, 1997; 349: 1436-42.
3. Khatri IA, Wasay M. Can we stop the stroke epidemic in Pakistan? J. Coll. Physicians Surg. Pak. 2011; 21: 195-6.
4. Kamal AK, Itrat A, Murtaza M, Khan M, Rasheed A, Ali A, et al. The burden of stroke and transient ischemic attack in Pakistan: a community-based prevalence stu-dy. BMC Neurol. 2009; 9: 58.
5. Patarroyo SXF, Anderson C. Blood pressure lowering in acute phase of stroke: latest evidence and clinical implications. Ther Adv Chronic Dis. 2012; 3: 163-71.
6. Willmot M, Leonardi – Bee J, Bath PM. High blood pressure in acute stroke and subsequent outcome: a sys-tematic review. Hypertension, 2004; 43: 18-24. 7. Qureshi AI, Ezzeddine MA, Nasar A, Suri MF, Kirmani JF, Hussein HM, et al. Prevalence of elevated blood pressure in 563,704 adult patients with stroke present-ing to the ED in the United States. Am. J. Emerg. Med. 2007; 25: 32-8. 8. Leonardi – Bee J, Bath PM, Phillips SJ, Sandercock PA. Blood pressure and clinical outcomes in the Inter-national Stroke Trial. Stroke, 2002; 33: 1315-20. 9. Broderick J, Brott T, Barsan W, Haley EC, Levy D, Marler J, et al. Blood pressure during the first minutes of focal cerebral ischemia. Ann. Emerg. Med. 1993; 22: 1438-43. 10. Christensen H, Meden P, Overgaard K, Boysen G. The course of blood pressure in acute stroke is related to the severity of the neurological deficits. Acta Neurol Scand. 2002; 106: 142-7.
11. Schrader J, Lüders S, Kulschewski A, Berger J, Zidek W, Treib J, et al. The ACCESS study: evaluation of acute Candesartan Cilexetil therapy in stroke survivors. Stroke, 2003; 34: 1699-1703. 12. He J, Zhang Y, Xu T, Zhao Q, Wang D, Chen CS, et al. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic str-oke: the CATIS randomized clinical trial. JAMA, 2014; 311: 479-89. 13. Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C, et al. Rapid blood-pressure lowering in pat-ients with acute intracerebral hemorrhage. N. Engl. J. Med. 2013; 368: 2355-65. 14. Sandset EC, Bath PM, Boysen G, Jatuzis D, Korv J, Luders S, et al. The angiotensin – receptor blocker can-desartan for treatment of acute stroke (SCAST): a ran-domised, placebo – controlled, double – blind trial. Lancet. 2011; 377: 741-50. 15. Zaidi Z, Hashim J, Iqbal M, Quadri KM. Paving the way for evidence-based medicine in Pakistan. J. Pak. Med. Assoc. 2007; 57: 556-60. 16. Khaliq N, Hussain N, Akhter R, Iqbal M. Knowledge and perceptions of physicians about evidence based management of hypertension in acute ischemic stroke patients. Rawal. Med. J. 2010; 35: 1-9.
17. Jafar TH, Levey AS, Jafary FH, White F, Gul A, Rah-bar MH, et al. Ethnic subgroup differences in hyperten-sion in Pakistan. J. Hypertens. 2003; 21: 905-12.
18. National Health Survey of Pakistan 1990 – 1994. Kara-chi, Pakistan: Pakistan Medical Research Council, 1998: 50. 19. He J, Zhang Y, Xu T, Zhao Q, Wang D, Chen CS, et al. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic str-oke the CATIS randomized clinical trial. JAMA, 2014; 311: 479-89. 20. Marwat MA, Usman M, Hussain M. Stroke and its relationship to risk factors. Gomal J. Med. Sci. 2009; 7: 17-21. 21. Shah SMA, Shah SMS, Saima Khan, Rehman SR, Khan ZA, Ahmed W, et al. Addressing the impact of stroke risk factors in a case control study in tertiary care hospitals: a case control study in Tertiary Care Hospi-tals of Peshawar, Khyber Pukhtoonkhwa (KPK) Pakis-tan. BMC Res Notes, 2013; 6: 268. 22. Taj F, Zahid R, Syeda UE, Murtaza M, Ahmed S, Kam-al AK. Risk factors of stroke in Pakistan: a dedicated stroke clinic experience. Can J Neurol Sci. 2010; 37: 252-7. 23. Leoo T, Lindgren A, Petersson J, Von Arbin M. Risk factors and treatment at recurrent stroke onset: results from the Recurrent Stroke Quality and Epidemiology (RESQUE) Study. Cerebrovasc. Dis. 2008; 25: 254-60. 24. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al. REACH Registry Investigators, Interna-tional prevalence, recognition, and treatment of cardio-vascular risk factors in outpatients with atherothrombo-sis. JAMA, 2006; 295: 180-9. 25. O'Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, et al. Risk factors for ischemic and intracerebral hemorrhagic stroke in 22 countries (the INTERSTROKE study): a case control study. Lancet, 2010; 376: 112-3. 26. Alla-ud-Din A, Muhammad AA, Hafeezullah A, Jawaid S, Muzafar S. Incidence of stroke in Context of hyper-tension in local population. Pak. J. Physiol. 2007; 3: 1.
27. Sandset EC, Murray G, Boysen G, Jatuzis D, Kõrv J, Lüders S, et al. Angiotensin receptor blockade in acute stroke. The Scandinavian Candesartan Acute Stroke Trial: rationale, methods and design of a multicentre, randomized – and placebo – controlled clinical trial (NCT00120003). Int J Stroke, 2010; 5: 423-7.
28. Geeganage C, Bath PM. Vasoactive drugs for acute stroke. Cochrane Database Syst. Rev. 2010; 7: CD002839.
Copyright (c) 2018 Pakistan Journal Of Neurological Surgery
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.